Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026)
Powered by 
Analysis
Neurocrine Biosciences (NBIX) EPS (Diluted) Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.59 Bn | 15.20 Bn | 935.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26.20% |
| Mar 31, 2026 | 42.40% |
| Dec 31, 2025 | -15.87% |
| Sep 30, 2025 | 39.65% |
| Jun 30, 2025 | 5.60% |
| Mar 31, 2025 | -27.53% |
| Dec 31, 2024 | 22.85% |
| Sep 30, 2024 | 17.32% |
| Jun 30, 2024 | 2.94% |
| Mar 31, 2024 | 18.87% |
| Dec 31, 2023 | 49.36% |
| Sep 30, 2023 | 9.40% |
| Jun 30, 2023 | 75.23% |
| Mar 31, 2023 | -11.05% |
| Dec 31, 2022 | 62.98% |
| Sep 30, 2022 | 49.60% |
| Jun 30, 2022 | 23.87% |
| Mar 31, 2022 | 16.62% |
| Dec 31, 2021 | 31.25% |
| Sep 30, 2021 | 20.26% |